TABLE 6.

Efficacy during treatment with alecitnib

ORR in overall population (n = 61)	47.5% (2CR + 27PR) (95% CI: 34.6%–60.7%)
ORR in patients with target lesions (n = 46)	ORR = 60.9% (1CR + 27PR) (95% CI: 45.4%–74.9%)
Median maximum tumor shrinkage rate (n = 46)	39% (range: −50%, 100)
Intracranial ORR in patients with CNS metastases (n = 38)	47.4% (7CR + 11PR) (95% CI: 31.0%–64.2%)
Intracranial ORR in patients with measurable CNS lesions (n = 29)	68.4% (2CR + 11PR) (95% CI: 43.4%–87.4%)
Improvement in CNS related symptoms (n = 10)
Significant improvement	9 (90%)
Moderate improvement	1 (10%)
No improvement	0
Deterioration	0